Trial · NCT03832647
Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne
NCT03832647, Phase 4, Completed, Vichy Laboratoires
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne. Trials, record NCT03832647. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03832647
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne
- NCT number
- NCT03832647
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 200 participants, actual
- Lead sponsor
- Vichy Laboratoires
- Conditions
- Acne
- Interventions
- Epiduo, Salicylic Acid, Hydréane légère
- First posted
- 2019-02-06
- Last updated
- 2021-10-18
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of the anti-acne efficacy 1 (number of the retentional and inflammatory lesions) | Week 0 (baseline) and Week 12 (final time point) | Change in the number of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) on face after a 12-week application period At Week 0 (before any application) and Week 12 (after a 12-week application period), a counting of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) will be performed by a Dermatologist. The counting will be broken down on several parts of the face (forehead, left and right cheeks and chin). |
| Secondary | Evaluation of the anti-acne efficacy 2 (number of the retentional and inflammatory lesions) | Week 4 and Week 8 (intermediary times point) | Change in the number of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) on face after 4 and 8-week application period At Week 4 (after a 4-week application) and Week 8 (after a 8-week application period), a counting of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) will be performed by a Dermatologist. The counting will be broken down on several parts of the face (forehead, left and right cheeks and chin). |
| Secondary | Change in the acne stage on face according to the Global Acne Evaluation scale after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), determination of the acne stage will be performed by the Dermatologist according to the Global Acne Evaluation scale (score min:0 to score max:5). More the score decreased, more the treatment is efficient. |
| Secondary | Change in the residual marks visibility after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the residual marks visibility of acne (hyperpigmentation) will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:numerous). More the score decreased, more the treatment is efficient. |
| Secondary | Change in the pores visibility after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the pores visibility will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:numerous). More the score decreased, more the treatment is efficient. |
| Secondary | Change in the skin shininess after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the skin shininess will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:high). More the score decreased, more the treatment is efficient. |
| Secondary | Change in skin greasiness after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse. The CL measurements (quantity of sebum (casual level)) will be taken using a SEBUMETER®. The unit is in µg sebum/cm² of the skin. Only one measurement per subject will be taken in the middle of the forehead. More the value decreased, less the skin is greasy. |
| Secondary | Change in skin moisturizing after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse. The measurements will be taken using a CM 825 PC CORNEOMETER®. The hydratation values are expressed in arbitrary units ranging from approximately 0 to 120. Three measurements per subject will be taken on the right cheekbone. More the value increased, more the skin is moisturize. |
| Secondary | Change in skin ph after 4, 8 and 12-week application period | Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) | At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse. The measurements will be taken using a SKIN PH METER 900®. The result will be expressed in pH units. Only one measurement per subject will be taken on the left cheek, near to the side of the nose. More the value decreased, more the ph is acid. |
| Secondary | Total number of hair follicles per cube at a mean depth of 38 µm after a 12-week application period | Week 0 (baseline) and Week 12 (final time point) | At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03832647
GET https://conductscience.org/api/trials/v1/NCT03832647/registered?page=2